Clinical Trial

A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated April 22, 2024 (before its estimated August 28, 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the safety and efficacy of SCTC21C in patients with CD38+ hematologic malignancies
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-02-07.
Status change: Not Yet Recruiting → Recruiting 2024-04-19
Trial Details
NCT Number NCT06252298
Lead Sponsor Sinocelltech Ltd.
Conditions Relapsed or Refractory Hematologic Malignancies
Enrollment 74 participants
Start Date 2024-02-28
Primary Completion 2025-08-28 (estimated)
Study Completion 2027-02-28 (estimated)
Updated on ClinicalTrials.gov 2024-04-22